Tocagen Inc. (NASDAQ:TOCA) Files An 8-K Results of Operations and Financial Condition

Item 2.02Results of Operations and Financial Condition.

On May 23, 2017, Tocagen Inc. issued a press release announcing
its financial results for the first quarter ended March 31, 2017.
A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit hereto are
being furnished and shall not be deemed to be filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liability of that
section, nor shall they be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.

About Tocagen Inc. (NASDAQ:TOCA)

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.

Tocagen Inc. (NASDAQ:TOCA) Recent Trading Information

Tocagen Inc. (NASDAQ:TOCA) closed its last trading session up +0.05 at 15.96 with 76,369 shares trading hands.